Form 4: Edwards Lifesciences Executive Equity Grant Disclosure

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, reported new equity grants and tax-related share dispositions.

Summary

• Donald E. Bobo Jr. received a grant of 7,850 restricted stock units (RSUs) on May 7, 2026.
• The executive was granted 44,000 employee stock options with an exercise price of $82.76.
• A total of 1,869 shares were withheld by the company to cover tax obligations related to the vesting of equity awards.
• Following these transactions, the reporting person holds 26,778.2532 shares directly, plus additional holdings in a 401(k) and trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through significant equity-based compensation.
• Retention of key leadership personnel through multi-year vesting schedules for options and RSUs.

Negatives

• Dilution impact from the issuance of new equity awards to management.
• Tax-related share withholding reduces the net increase in direct ownership for the executive.

Risks

• Performance-based restricted stock units are subject to achievement of goals, with potential vesting ranging from 0% to 200% of target.
• Market price volatility could impact the ultimate value of the granted options and RSUs.

Future Outlook

The executive's compensation is tied to long-term performance goals over a three-year period, with vesting schedules extending through 2033 for options.

Management Comments

• The equity grants are issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation practices within the medical device sector, where long-term equity incentives are used to retain high-level strategic talent.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with compensation structures at peer companies like Medtronic and Boston Scientific.
• Vesting schedules of 3-4 years are standard practice for executive retention in the healthcare technology industry.

Stakeholder Impact

• Shareholders should note the dilution associated with new equity grants.
• Employees and management are incentivized toward long-term corporate performance.

Next Steps

• Vesting of stock options beginning May 2027.
• Performance evaluation for RSU vesting scheduled for May 2029.

Key Dates

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Executive Compensation, Equity Grants, Stock Options